Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32679621 | 0.85 | ACACB (0.46) | GPR119CYP11B2ACACBMAPTTSHR | |
| SCHEMBL30135848 | 0.85 | LMNA (0.39) | GPR119PIK3R1PIK3CATSHRHSD17B10 | |
| SCHEMBL28614518 | 0.80 | CYP11B2 (0.51) | GPR119CYP11B2ACACBMAPT | |
| SCHEMBL22720703 | 0.80 | CYP11B2 (0.49) | GPR119CYP11B2ACACBMAPTRET | |
| SCHEMBL12723192 | 0.78 | CYP3A4 (0.48) | GPR119CYP11B2ACACBMAPT | |
| SCHEMBL29058892 | 0.76 | CYP11B2 (0.42) | GPR119CYP11B2ACACBRET | |
| SCHEMBL22720835 | 0.75 | GPR119 (0.50) | GPR119CYP11B2ACACBMAPTTSHR | |
| SCHEMBL23742297 | 0.75 | CYP11B2 (0.56) | GPR119CYP11B2ACACBPIK3R1PIK3CA | |
| SCHEMBL25819551 | 0.73 | L3MBTL1 (0.35) | ACACBPIK3R1PIK3CA | |
| SCHEMBL484867 | 0.73 | CYP11B2 (0.54) | GPR119CYP11B2ACACBMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116322700-B | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-08-20 | — | — | CN | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| CN-116322700-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | GPR119 4626/4885CYP11B2 2597/4885ACACB 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.